Survival after treatment with phenylacetate and benzoate for urea-cycle disorders

Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, United States
New England Journal of Medicine (Impact Factor: 54.42). 05/2007; 356(22):2282-92. DOI: 10.1056/NEJMoa066596
Source: PubMed

ABSTRACT The combination of intravenous sodium phenylacetate and sodium benzoate has been shown to lower plasma ammonium levels and improve survival in small cohorts of patients with historically lethal urea-cycle enzyme defects.
We report the results of a 25-year, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia.
Overall survival was 84% (250 of 299 patients). Ninety-six percent of the patients survived episodes of hyperammonemia (1132 of 1181 episodes). Patients over 30 days of age were more likely than neonates to survive an episode (98% vs. 73%, P<0.001). Patients 12 or more years of age (93 patients), who had 437 episodes, were more likely than all younger patients to survive (99%, P<0.001). Eighty-one percent of patients who were comatose at admission survived. Patients less than 30 days of age with a peak ammonium level above 1000 micromol per liter (1804 microg per deciliter) were least likely to survive a hyperammonemic episode (38%, P<0.001). Dialysis was also used in 56 neonates during 60% of episodes and in 80 patients 30 days of age or older during 7% of episodes.
Prompt recognition of a urea-cycle disorder and treatment with both sodium phenylacetate and sodium benzoate, in conjunction with other therapies, such as intravenous arginine hydrochloride and the provision of adequate calories to prevent catabolism, effectively lower plasma ammonium levels and result in survival in the majority of patients. Hemodialysis may also be needed to control hyperammonemia, especially in neonates and older patients who do not have a response to intravenous sodium phenylacetate and sodium benzoate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Human adults produce around 1000mmol of ammonia daily. Some is reutilized in biosynthesis. The remainder is waste and neurotoxic. Eventually most is excreted in urine as urea, together with ammonia used as a buffer. In extrahepatic tissues, ammonia is incorporated into nontoxic glutamine and released into blood. Large amounts are metabolized by the kidneys and small intestine. In the intestine, this yields ammonia, which is sequestered in portal blood and transported to the liver for ureagenesis, and citrulline, which is converted to arginine by the kidneys. The amazing developments in NMR imaging and spectroscopy and molecular biology have confirmed concepts derived from early studies in animals and cell cultures. The processes involved are exquisitely tuned. When they are faulty, ammonia accumulates. Severe acute hyperammonemia causes a rapidly progressive, often fatal, encephalopathy with brain edema. Chronic milder hyperammonemia causes a neuropsychiatric illness. Survivors of severe neonatal hyperammonemia have structural brain damage. Proposed explanations for brain edema are an increase in astrocyte osmolality, generally attributed to glutamine accumulation, and cytotoxic oxidative/nitrosative damage. However, ammonia neurotoxicity is multifactorial, with disturbances also in neurotransmitters, energy production, anaplerosis, cerebral blood flow, potassium, and sodium. Around 90% of hyperammonemic patients have liver disease. Inherited defects are rare. They are being recognized increasingly in adults. Deficiencies of urea cycle enzymes, citrin, and pyruvate carboxylase demonstrate the roles of isolated pathways in ammonia metabolism. Phenylbutyrate is used routinely to treat inherited urea cycle disorders, and its use for hepatic encephalopathy is under investigation. © 2014 Elsevier Inc. All rights reserved.
    Advances in clinical chemistry 01/2014; 67:73-150. DOI:10.1016/bs.acc.2014.09.002 · 4.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ammonia is a key neurotoxin involved in the neurological complications of the liver. Elevated ammonia leads to hyperammonemic condition which affects several important central nervous system functions. Fisetin is one of the naturally occurring flavonoids found in fruits and vegetables; it exhibits a wide variety of therapeutic benefits such as anticancer, antidiabetic, antioxidant, antiangiogenic, and neuroprotective effects. In this present study, chronotherapeutic efficacy of fisetin on ammonium chloride (AC)-induced hyperammonemic rats was aimed to establish the maximum drug effect by determining the best fitting biological time for drug dosing that helps to increase the therapeutic index of fisetin. The antihyperammonemic effect of fisetin was determined by administering (50 mg/kg b.w. oral) to rats at 06:00, 12:00, 18:00 and 24:00 h against AC (100 mg/kg b.w. i.p.) induced hyperammonemic Wistar rats (180-200 g). Amelioration of pathophysiological conditions of AC-induced hyperammonemia rats by fisetin at different time points (06:00, 12:00, 18:00 and 24:00 h) were measured by assessing the circulatory levels of ammonia, urea, uric acid, creatinine, bilirubin, and liver marker enzymes. Fisetin administration at 24:00 h showed more significant effects on those parameters than the other time points (p
    Biological Rhythm Research 08/2013; 44(4):577-588. DOI:10.1080/09291016.2012.730890 · 1.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Advances in the diagnosis and treatment of urea cycle disorders (UCDs) have led to a higher survival rate. The purpose of this study is to describe the characteristics of patients with urea cycle disorders in Spain.Methods Observational, cross-sectional and multicenter study. Clinical, biochemical and genetic data were collected from patients with UCDs, treated in the metabolic diseases centers in Spain between February 2012 and February 2013, covering the entire Spanish population. Heterozygous mothers of patients with OTC deficiency were only included if they were on treatment due to being symptomatic or having biochemistry abnormalities.Results104 patients from 98 families were included. Ornithine transcarbamylase deficiency was the most frequent condition (64.4%) (61.2% female) followed by type 1 citrullinemia (21.1%) and argininosuccinic aciduria (9.6%). Only 13 patients (12.5%) were diagnosed in a pre-symptomatic state. 63% of the cases presented with type intoxication encephalopathy. The median ammonia level at onset was 298 ¿mol/L (169-615). The genotype of 75 patients is known, with 18 new mutations having been described. During the data collection period four patients died, three of them in the early days of life. The median current age is 9.96 years (5.29-18), with 25 patients over 18 years of age. Anthropometric data, expressed as median and z-score for the Spanish population is shown. 52.5% of the cases present neurological sequelae, which have been linked to the type of disease, neonatal onset, hepatic failure at diagnosis and ammonia values at diagnosis. 93 patients are following a protein restrictive diet, 0.84 g/kg/day (0.67-1.10), 50 are receiving essential amino acid supplements, 0.25 g/kg/day (0.20-0.45), 58 arginine, 156 mg/kg/day (109-305) and 45 citrulline, 150 mg/kg/day (105-199). 65 patients are being treated with drugs: 4 with sodium benzoate, 50 with sodium phenylbutyrate, 10 with both drugs and 1 with carglumic acid.Conclusions Studies like this make it possible to analyze the frequency, natural history and clinical practices in the area of rare diseases, with the purpose of knowing the needs of the patients and thus planning their care.
    Orphanet Journal of Rare Diseases 11/2014; 9(1):187. DOI:10.1186/s13023-014-0187-4 · 3.96 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014